Neurological disorders

Using dental antibiotic prophylaxis for hydrocephalus shunts

13 December 2024Considerations for whether the risk of shunt infection from transient bacteraemia during invasive dental procedures warrants non-routine antibiotic prophylaxis.

Using benzodiazepines during breastfeeding

15 February 2024Lorazepam and oxazepam are the preferred benzodiazepines during breast feeding, if clinically appropriate. Recommendations apply to full term, healthy infants.

Using antidepressants for depression in people with epilepsy

14 May 2021Antidepressant use requires special consideration in people with epilepsy. Treating depression in stable epilepsy is covered.

Treating insomnia during breastfeeding

8 March 2024Zopiclone and zolpidem are preferred for the short-term management of insomnia during breastfeeding. Recommendations apply to full term and healthy infants.

The licence and supporting evidence for natalizumab biosimilar

6 February 2024One licensed natalizumab biosimilar is available: Tyruko. Learn about the licensed indications and supporting evidence.

Switching brand and generic anti-seizure medicines for epilepsy

12 August 2025Switching between different manufacturers' anti-seizure medicines requires individual assessments and careful consideration about whether it will be suitable.

Preparing to use natalizumab biosimilar

6 February 2024Natalizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team.

Parkinson’s disease medicines in swallowing difficulties

13 June 2022Guidance to help you ensure your patients with Parkinson’s Disease are able to get the most from their medicines if they develop swallowing difficulties

Parkinson's disease in primary care

20 June 2023An on the couch conversation between consultant and primary care pharmacists about improving confidence to optimise medicines for people with Parkinson’s

Good governance when implementing natalizumab biosimilar

6 February 2024Governance should consider processes for approval, procurement and supply, prescribing and administration, monitoring and pharmacovigilance.